左乙拉西坦
医学
癫痫
儿科
神经影像学
病态的
脑电图
丙戊酸
痴呆
发作类型
肌阵挛
萎缩
精神科
内科学
疾病
作者
Clarissa Corniello,Fedele Dono,Giacomo Evangelista,Stefano Consoli,Sibilla De Angelis,Sara Cipollone,Davide Liviello,Gaetano Polito,Sara Melchiorre,Mirella Russo,Alberto Granzotto,Francesca Anzellotti,Marco Onofrj,Astrid Thomas,Stefano L. Sensi
标识
DOI:10.1016/j.seizure.2023.05.017
摘要
Introduction The late onset myoclonic epilepsy in Down Syndrome (LOMEDS) is a peculiar epilepsy type characterized by cortical myoclonus and generalized tonic-clonic seizures (GTCS), in people suffering from cognitive decline in Down syndrome (DS). In this review, we analyzed available data on the diagnostic and therapeutic management of individuals with LOMEDS. Methods We performed a systematic search of the literature to identify the diagnostic and therapeutic management of patients with LOMEDS. The following databases were used: PubMed, Google Scholar, EMBASE, CrossRef. The protocol was registered on PROSPERO (registration code: CRD42023390748). Results Data from 46 patients were included. DS was diagnosed according to the patient's clinical and genetic characteristics. Diagnosis of Alzheimer's dementia (AD) preceded the onset of epilepsy in all cases. Both myoclonic seizures (MS) and generalized tonic-clonic seizures (GTCS) were reported, the latter preceding the onset of MS in 28 cases. EEG was performed in 45 patients, showing diffuse theta/delta slowing with superimposed generalized spike-and-wave or polyspike-and-wave. A diffuse cortical atrophy was detected in 34 patients on neuroimaging. Twenty-seven patients were treated with antiseizure medication (ASM) monotherapy, with reduced seizure frequency in 17 patients. Levetiracetam and valproic acid were the most used ASMs. Up to 41% of patients were unresponsive to first-line treatment and need adjunctive therapy for seizure control. Conclusions AD-related pathological changes in the brain may play a role in LOMEDS onset, although the mechanism underlying this phenomenon is still unknown. EEG remains the most relevant investigation to be performed. A significant percentage of patients developed a first-line ASM refractory epilepsy. ASMs which modulate the glutamatergic system may represent a good therapeutic option.
科研通智能强力驱动
Strongly Powered by AbleSci AI